HealthEquity (FRA:2HE) Current Deferred Revenue: €0 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2HE HealthEquity Inc FRA:2HE
93 GF Score
Price €90.50
GF Value €88.69
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HealthEquity Current Deferred Revenue?

HealthEquity FRA:2HE 93 Current Deferred Revenue is €0 Mil as of Apr. 2026. GuruFocus rates FRA:2HE with a GF Score™ of 93/100 and a GF Value™ of €88.69 (Fairly Valued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

HealthEquity's current deferred revenue for the quarter that ended in Apr. 2026 was €0 Mil.

HealthEquity Current Deferred Revenue Related Terms

HealthEquity Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for HealthEquity's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HealthEquity Current Deferred Revenue Chart

HealthEquity Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HealthEquity Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2HE
93GF Score
HealthEquity Inc FRA:2HE
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0 Mil mean?
HealthEquity (FRA:2HE) has a Current Deferred Revenue of €0 Mil as of Apr. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on HealthEquity and its competitors.
Is HealthEquity's Current Deferred Revenue too high?
HealthEquity's current Current Deferred Revenue is €0 Mil. Overall, HealthEquity has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's Current Deferred Revenue compare to TEM and TXG?
HealthEquity's Current Deferred Revenue of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on HealthEquity and its competitors. HealthEquity's current Current Deferred Revenue is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
Based on GuruFocus' analysis, HealthEquity (FRA:2HE) is currently considered Fairly Valued. The stock's GF Value™ is €88.69, compared to a current price of €90.50 — trading 2% above its estimated fair value. The current Current Deferred Revenue is €0 Mil. HealthEquity's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current Current Deferred Revenue is €0 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HealthEquity (FRA:2HE) Overvalued in 2026?

Based on GuruFocus' analysis, HealthEquity stock appears to be overvalued. The current stock price of €90.50 is trading 2% above its estimated GF Value™ of €88.69. GuruFocus considers HealthEquity to be Fairly Valued.

Key valuation signals for FRA:2HE:

  • Current Deferred Revenue: €0 Mil
  • GF Value™: €88.69 vs. price of €90.50 (2% above fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HealthEquity Business Description

Other Exchanges HQY:USA
Address 15 West Scenic Pointe Drive, Suite 100, Draper, UT, USA, 84020
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
93GF Score

Get the complete analysis for FRA:2HE

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€90.50
Price
€88.69
GF Value